Acepodia is emerging as one of the world’s few developers of antibody-drug conjugates (ADCs) preparing to advance into the clinic with a dual payload-fixed design of targeted cancer therapy.
Key Takeaways
- Acepodia is progressing dual-payload antibody-drug conjugates into the clinic based on its proprietary Antibody-Dual-Drugs Conjugation platform, which aims to improve efficacy over existing single-payload ADCs.
Based out of Taipei, Taiwan and Alameda, CA in the US, the small bioventure is pinning high hopes on its...